MAY 03, 2017 1:47 PM PDT

Lung Cancer's Return Can be Predicted a Year in Advance

WRITTEN BY: Xuan Pham

Results from a new study could help doctors detect the recurrence of lung cancer up to a year before traditional tests. Such technology would allow patients to stay one step ahead of the cancer in terms of treatment and survival outcomes.

The new test relies on circulating tumor DNA (ctDNA). Also known as cell-free tumor DNA, ctDNA is genetic material that’s freely floating in the bloodstream of cancer patients. The source of ctDNA is the tumor, where dead tumor cells break open and release the tumor DNA into the patient’s blood.

Image credit: pixabay.com

Led by Charles Swanton from the Francis Crick Institute, researchers analyzed blood samples from 100 patients with non-small cell lung cancer, the most common type of lung cancer. These patients also provided tumor samples, from which the researcher used to build a cancer genetic profile unique to each patient. Then, they hunted for these genetic mutations in the patient’s blood biopsies.

“First, we’re looking at blood samples taken before the patients had surgery to remove their tumours,” explained Christopher Abbosh, the study’s lead author. “We want to see what features of the tumour are associated with the release of ctDNA into the circulation. Next, we want to see which parts of the tumor’s genetic make-up, or ‘evolutionary tree’, can be detected in the blood. Finally, we want to find out what this DNA could tell us after the patients have had surgery.”

This in-depth analysis dramatically increased the sensitivity of detecting ctDNA and capturing the very early stages of lung cancer relapsing. Almost all of the patients with squamous cell type lung cancer had tumor DNA in their blood.

“Many studies have suggested that tumour DNA might be released when cancer cells are breaking down and becoming necrotic,” said Abbosh. “Squamous cell tumours are known to be a necrotic type of non-small cell lung cancer, so this might explain why we could detect tumour DNA earlier in these patients.

The biggest advantage of this new technique is early detection. The researchers report that the blood test catches these tumors when they’re still tiny, occupying just 0.3 cubic millimeters. Just as it’s easier to contain small fires than big ones, treating cancer when it’s small and nearly invisible is likely to yield better outcomes. "We hope that by treating the disease when there are very few cells in the body that we'll be able to increase the chance of curing a patient,” said Swanton.

"We can identify patients to treat even if they have no clinical signs of disease, and also monitor how well therapies are working,” said Abbosh. "This represents new hope for combating lung cancer relapse following surgery, which occurs in up to half of all patients.”

But some big questions are still unanswered. "We can now set up clinical trials to ask the fundamental question - if you treat people's disease when there's no evidence of cancer on a CT scan or a chest X-ray can we increase the cure rate?” said Swanton.

Additional sources: BBC

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 31, 2021
Genetics & Genomics
Targeting Aneuploidy in Cancer Cells
JAN 31, 2021
Targeting Aneuploidy in Cancer Cells
Cancer is typically related to problems in cells' genomes that lead to uncontrolled cell growth, and the formation of tu ...
FEB 12, 2021
Cancer
A behavioral science approach to FIT kits
FEB 12, 2021
A behavioral science approach to FIT kits
Researchers from the Perelman School of Medicine at the University of Pennsylvania have a new strategy to promoting colo ...
MAR 04, 2021
Clinical & Molecular DX
Is the Cancer Treatment Working? Liquid Biopsies Provide Answers.
MAR 04, 2021
Is the Cancer Treatment Working? Liquid Biopsies Provide Answers.
A newly-developed tool could help physicians monitor the performance of colorectal cancer therapies simply by examining ...
MAR 09, 2021
Cancer
Chinese Americans face high barriers for cancer screening
MAR 09, 2021
Chinese Americans face high barriers for cancer screening
A study recently published in the Asian Pacific Journal of Cancer Prevention reports that Chinese Americans are fac ...
MAY 07, 2021
Cancer
Pandemic times haven't been fun for anyone, but they've been especially hard for cancer patients
MAY 07, 2021
Pandemic times haven't been fun for anyone, but they've been especially hard for cancer patients
The pandemic hit everyone hard on many levels; now, new research from UCSF published in Cancer reports that cancer patie ...
MAY 10, 2021
Cell & Molecular Biology
Getting RNA-Based Medicine Past the Blood-Brain Barrier
MAY 10, 2021
Getting RNA-Based Medicine Past the Blood-Brain Barrier
RNA molecules serve several functions, one of which is to help the cell generate proteins from active genes. It also may ...
Loading Comments...